<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">World J Surg Oncol</journal-id>
      <journal-title>World Journal of Surgical Oncology</journal-title>
      <issn pub-type="epub">1477-7819</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
        <publisher-loc>London</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">17634124</article-id>
      <article-id pub-id-type="pmc">1939849</article-id>
      <article-id pub-id-type="publisher-id">1477-7819-5-79</article-id>
      <article-id pub-id-type="doi">10.1186/1477-7819-5-79</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Successful paclitaxel-based chemotherapy for an alpha-fetoprotein-producing gastric cancer patient with multiple liver metastases</article-title>
      </title-group>
      <contrib-group>
        <contrib id="A1" contrib-type="author">
          <name>
            <surname>Takeyama</surname>
            <given-names>Hiromitsu</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>takeyama@med.nagoya-cu.ac.jp</email>
        </contrib>
        <contrib id="A2" corresp="yes" contrib-type="author">
          <name>
            <surname>Sawai</surname>
            <given-names>Hirozumi</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>sawai@med.nagoya-cu.ac.jp</email>
        </contrib>
        <contrib id="A3" contrib-type="author">
          <name>
            <surname>Wakasugi</surname>
            <given-names>Takehiro</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>wakasugi@med.nagoya-cu.ac.jp</email>
        </contrib>
        <contrib id="A4" contrib-type="author">
          <name>
            <surname>Takahashi</surname>
            <given-names>Hiroki</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>takahasi@med.nagoya-cu.ac.jp</email>
        </contrib>
        <contrib id="A5" contrib-type="author">
          <name>
            <surname>Matsuo</surname>
            <given-names>Yoichi</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>matsuo@med.nagoya-cu.ac.jp</email>
        </contrib>
        <contrib id="A6" contrib-type="author">
          <name>
            <surname>Ochi</surname>
            <given-names>Nobuo</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>nochi@med.nagoya-cu.ac.jp</email>
        </contrib>
        <contrib id="A7" contrib-type="author">
          <name>
            <surname>Yasuda</surname>
            <given-names>Akira</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>a-yasuda@med.nagoya-cu.ac.jp</email>
        </contrib>
        <contrib id="A8" contrib-type="author">
          <name>
            <surname>Sato</surname>
            <given-names>Mikinori</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>miki@med.nagoya-cu.ac.jp</email>
        </contrib>
        <contrib id="A9" contrib-type="author">
          <name>
            <surname>Okada</surname>
            <given-names>Yuji</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>yuji@med.nagoya-cu.ac.jp</email>
        </contrib>
        <contrib id="A10" contrib-type="author">
          <name>
            <surname>Funahashi</surname>
            <given-names>Hitoshi</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>funa84@med.nagoya-cu.ac.jp</email>
        </contrib>
        <contrib id="A11" contrib-type="author">
          <name>
            <surname>Akamo</surname>
            <given-names>Yoshimi</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>akamo@med.nagoya-cu.ac.jp</email>
        </contrib>
        <contrib id="A12" contrib-type="author">
          <name>
            <surname>Manabe</surname>
            <given-names>Tadao</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>mnb@med.nagoya-cu.ac.jp</email>
        </contrib>
      </contrib-group>
      <aff id="I1"><label>1</label>Department of Gastroenterological Surgery, Nagoya City University Graduate School of Medical Sciences, Kawasumi 1, Mizuho-cho, Mizuho-ku, Nagoya 4678601, Japan</aff>
      <pub-date pub-type="collection">
        <year>2007</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>16</day>
        <month>7</month>
        <year>2007</year>
      </pub-date>
      <volume>5</volume>
      <fpage>79</fpage>
      <lpage>79</lpage>
      <ext-link ext-link-type="uri" xlink:href="http://www.wjso.com/content/5/1/79"/>
      <history>
        <date date-type="received">
          <day>21</day>
          <month>3</month>
          <year>2007</year>
        </date>
        <date date-type="accepted">
          <day>16</day>
          <month>7</month>
          <year>2007</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright &#xA9; 2007 Takeyama et al; licensee BioMed Central Ltd.</copyright-statement>
        <copyright-year>2007</copyright-year>
        <copyright-holder>Takeyama et al; licensee BioMed Central Ltd.</copyright-holder>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0">
          <p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p>
          <!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author>
               Takeyama
               Hiromitsu
               
               takeyama@med.nagoya-cu.ac.jp
            </dc:author><dc:title>
            Successful paclitaxel-based chemotherapy for an alpha-fetoprotein-producing gastric cancer patient with multiple liver metastases
         </dc:title><dc:date>2007</dc:date><dcterms:bibliographicCitation>World Journal of Surgical Oncology 5(1): 79-. (2007)</dcterms:bibliographicCitation><dc:identifier type="sici">1477-7819(2007)5:1&#x0003c;79&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1477-7819</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>-->
        </license>
      </permissions>
      <abstract>
        <sec>
          <title>Background</title>
          <p>Alpha-fetoprotein (AFP)-producing gastric cancer is known to frequently cause multiple liver metastases and to have an extremely poor prognosis.</p>
        </sec>
        <sec>
          <title>Case presentation</title>
          <p>A 64-year-old Japanese man admitted to our hospital was diagnosed with gastric cancer with liver metastases. He underwent a total gastrectomy with splenectomy, and pathological stage IV disease according to the classification proposed by the Japanese Gastric Cancer Association was assigned. The histological diagnosis was poorly differentiated adenocarcinoma, and tumor production of AFP was confirmed by immunohistochemical staining. Following surgery, the patient received combination chemotherapy consisting of TS-1 and paclitaxel. Initially, AFP levels decreased dramatically and computed tomography (CT) revealed regression of liver metastases. However, multiple new liver metastases appeared and serum AFP levels increased after 5 months. A regimen of 5-FU plus paclitaxel followed by paclitaxel monotherapy was used next. Serum AFP levels once again decreased and CT showed regression or disappearance of liver metastases. The patient currently has a very good quality of life, and is receiving weekly paclitaxel monotherapy as an outpatient. No progression of liver metastases has been observed to date.</p>
        </sec>
        <sec>
          <title>Conclusion</title>
          <p>We consider this rare case to have significant value with respect to treatment of AFP-producing gastric cancer with multiple liver metastases, and propose that combining surgery with chemotherapeutic agents such as paclitaxel may lead to a better prognosis in such cases.</p>
        </sec>
      </abstract>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>Background</title>
      <p>Alpha-fetoprotein (AFP), which was initially identified from human fetal tissue, is normally produced in the fetal liver and yolk sac [<xref ref-type="bibr" rid="B1">1</xref>]. Since Bourreille <italic>et al., </italic>first reported a patient with gastric tumors that produced AFP, a considerable number of such patients have been identified [<xref ref-type="bibr" rid="B2">2</xref>]. AFP-producing gastric cancer is known to frequently cause multiple liver metastases and to have an extremely poor prognosis [<xref ref-type="bibr" rid="B3">3</xref>-<xref ref-type="bibr" rid="B6">6</xref>]. It has been reported that AFP-producing gastric cancer has high proliferative activity, weak apoptotic activity, and rich neovascularization compared with AFP-negative gastric cancer [<xref ref-type="bibr" rid="B4">4</xref>]. It is likely that these biological observations reflect the aggressive clinical behavior of AFP-producing gastric cancers.</p>
      <p>There is no standard chemotherapy available for this disease, although the following regimens have demonstrated efficacy in a small number of cases: EAP (etoposide [ETP], adriamycin, and cisplatin [CDDP]), FAP (5-fluorouracil [5-FU], epirubicin [EPI], and CDDP), and FAP (5-FU, adriamycin, and CDDP) [<xref ref-type="bibr" rid="B7">7</xref>-<xref ref-type="bibr" rid="B9">9</xref>]. The therapeutic efficacy of irinotecan hydrochloride (CPT-11) and paclitaxel [<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B11">11</xref>] in this disease state has also been recently reported.</p>
      <p>In this report, we describe a case with AFP-producing gastric cancer that responded to combination 5-FU/paclitaxel chemotherapy followed by a bi-weekly course of paclitaxel monotherapy.</p>
    </sec>
    <sec>
      <title>Case presentation</title>
      <p>A 64-year-old Japanese man admitted to Nagoya City University Hospital because of upper abdominal pain was diagnosed with gastric cancer with liver metastases. His family history was unremarkable. Laboratory data on admission revealed liver dysfunction as follows: serum glutamic oxaloacetic transaminase (SGOT), 125 U/L (normal range, 10&#x2013;33 U/L); glutamic pyruvic transferase (SGPT), 252 U/L (normal range, 6&#x2013;37 U/L); &#x3B3;-glutamyl transpeptidase (&#x3B3;-GTP), 1435 U/L (normal range, 10&#x2013;47 U/L); alkaliphosphatase (ALP), 988 U/L (normal range, 115&#x2013;359 U/L). AFP and carcinoembryonic antigen (CEA) levels were 1497.8 ng/ml and 72.7 ng/ml, respectively. Abdominal computed tomography (CT) showed enhanced thickness of the gastric wall and multiple liver metastases (Figure <xref ref-type="fig" rid="F1">1A</xref>). Gastroscopy revealed a Borrmann type III tumor on the lesser curvature in the midportion of the stomach (Figure <xref ref-type="fig" rid="F1">1B</xref>), which was diagnosed as gastric carcinoma upon histological examination of a biopsy specimen. After informed consent with enough detailed explanation about the patient's disease, he wished a surgical treatment strongly. The patient underwent surgical resection (total gastrectomy with splenectomy). The pathological stage was IV: T3, N1, H1, P0 according to the classification proposed by the Japanese Gastric Cancer Association [<xref ref-type="bibr" rid="B12">12</xref>], and the histological diagnosis was poorly differentiated adenocarcinoma. Lymphatic invasion was moderate and venous invasion was negative. Tumor production of AFP was confirmed by immunohistochemical staining (Figure <xref ref-type="fig" rid="F2">2A</xref> and <xref ref-type="fig" rid="F2">2B</xref>).</p>
      <fig position="float" id="F1">
        <label>Figure 1</label>
        <caption>
          <p><bold>(A) </bold>Abdominal computed tomography (CT) revealed enhanced thickness of the gastric wall and multiple liver metastases. <bold>(B) </bold>Gastroscopy revealed a Borrmann type III tumor on the lesser curvature in the midportion of the stomach.</p>
        </caption>
        <graphic xlink:href="1477-7819-5-79-1"/>
      </fig>
      <fig position="float" id="F2">
        <label>Figure 2</label>
        <caption>
          <p>Resected specimen of stomach was fixed with 10% formalin and embedded in paraffin. Sections were stained with <bold>(A) </bold>hematoxylin-eosin staining (&#xD7; 200) , <bold>(B) </bold>alpha-fetoprotein (&#xD7; 200), or <bold>(C) </bold>negative control IgG (&#xD7; 200).</p>
        </caption>
        <graphic xlink:href="1477-7819-5-79-2"/>
      </fig>
      <p>The patient was treated with one course of paclitaxel (80 mg on days 1 and 8) and TS-1 (100 mg/day for 2 weeks and discontinuation for 1 week) after surgery. After 3 months, the level of AFP had remarkably decreased from 4344.0 ng/ml to 418.9 ng/ml. After 4 months, CT revealed regression of liver metastases (Figure <xref ref-type="fig" rid="F3">3A</xref>). However, after 5 months, multiple new liver metastases were apparent (Figure <xref ref-type="fig" rid="F3">3B</xref>) and serum AFP had increased to 8189.0 ng/ml. Furthermore, an ileus occurred due to peritonitis carcinomatous. We therefore tried a regimen of 5-FU (500 mg/day via continuous infusion for 7 days) plus paclitaxel (120 mg weekly) at weekly intervals. After one treatment course, 5-FU administration was stopped but paclitaxel (120 mg) monotherapy was continued for 6 weeks. Serum AFP levels decreased again (to 709.7 ng/ml) and CT revealed that the liver metastases had either regressed or disappeared (Figure <xref ref-type="fig" rid="F3">3C</xref>). The patient currently has a very good quality of life, and is receiving weekly paclitaxel monotherapy as an outpatient. Three months have passed since 5-FU/paclitaxel treatment was started; no progression of liver metastases has been observed to date.</p>
      <fig position="float" id="F3">
        <label>Figure 3</label>
        <caption>
          <p><bold>(A) </bold>Enhanced CT revealed that liver metastases had decreased in size following initial therapy. <bold>(B) </bold>After 5 months of treatment, multiple liver metastases reappeared in segments 1, 3, and 5. (C) Following second-line treatment with 5-FU/paclitaxel and paclitaxel monotherapy, liver metastases either regressed or disappeared.</p>
        </caption>
        <graphic xlink:href="1477-7819-5-79-3"/>
      </fig>
    </sec>
    <sec>
      <title>Discussion</title>
      <p>AFP-producing gastric cancers should be divided in to three subtypes: 1) hepatoid type; 2) yolk sac tumor-like type; and 3) fetal gastrointestinal type [<xref ref-type="bibr" rid="B13">13</xref>]. The hepatoid type was the most common one of AFP-producing gastric cancer, and they were described as hepatoid adenocarcinoma that means primary gastric cancer that are characterized by both hepatoid differentiation and the production of AFP [<xref ref-type="bibr" rid="B14">14</xref>,<xref ref-type="bibr" rid="B15">15</xref>]. Our case had the tumor that was classified as having a hepatoid subtype. Unfortunately, most hepatoid type tumor tends to be highly malignant [<xref ref-type="bibr" rid="B13">13</xref>]. AFP-producing gastric cancer has a high proliferative activity, weak apoptosis, and rich neovascularization [<xref ref-type="bibr" rid="B4">4</xref>]. Recent reports described that some factors associated with mitosis, cell movement, proliferative activity, and tumor progression such as Ki-67, hepatocyte growth factor (HGF) and its receptor, c-Met, vascular endothelial growth factor (VEGF) and its isoform VEGF-C, were found to be highly expressed in AFP-producing gastric cancer and might contribute to the poor prognosis and drug resistance of this tumor [<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B16">16</xref>,<xref ref-type="bibr" rid="B17">17</xref>].</p>
      <p>Few successful treatment options exist for AFP-producing gastric cancer. While surgical resection is considered to be somewhat effective, approximately 50% of patients who undergo curative resection of the primary tumor eventually die due to recurrence, most of them with multiple liver metastases [<xref ref-type="bibr" rid="B18">18</xref>]. Indeed, AFP-producing gastric cancer is associated with a high incidence of multiple liver metastases, which render resection impossible. Moreover, AFP-producing gastric cancer is reported to respond poorly to a number of chemotherapy regimens. The use of various chemotherapeutic protocols that are active in other types of cancer have been reported, although their efficacy in gastric cancer is controversial [<xref ref-type="bibr" rid="B7">7</xref>-<xref ref-type="bibr" rid="B11">11</xref>]. Some investigators have reported that AFP-producing gastric cancer can be treated successfully with preoperative (i.e., neoadjuvant) combination chemotherapy with EPI, 5-FU, and leucovorin (LV) [<xref ref-type="bibr" rid="B19">19</xref>]. Kochi <italic>et al., </italic>have also reported the use of a combination chemotherapy regimen consisting of 5-FU, LV, ETP, and CDDP (designated as the FLEP regimen) for inoperable stage IV gastric cancer [<xref ref-type="bibr" rid="B20">20</xref>,<xref ref-type="bibr" rid="B21">21</xref>]. FLEP chemotherapy was more effective for stage IV AFP-producing gastric cancer than for stage IV non-AFP-producing gastric cancer, and it improved the prognosis of AFP-producing gastric cancer due to downstaging.</p>
      <p>TS-1 has shown superior results in the treatment of gastric cancer both as monotherapy and in combination with other agents. In a phase II clinical trial in Japan, single administration of TS-1 yielded a higher response rate (46.5%, 60/129 cases), longer median survival time (MST; 8.1 months), and lower incidence of adverse events compared to historical controls (e.g., 5-FU, methotrexate + LV, CDDP). It has proven to be one of the most promising new anti neoplastic agents [<xref ref-type="bibr" rid="B22">22</xref>]. However, in poorly differentiated gastric cancer, the agents described above are only effective in a small proportion of patients. Several case reports have demonstrated the efficacy of TS-1 monotherapy against malignant ascites. The novel antimitotic agent paclitaxel inhibits cell division by promoting tubulin polymerization and stabilizing microtubules [<xref ref-type="bibr" rid="B23">23</xref>]. This agent has been used as second-line treatment in patients with gastric cancer, particularly for cases refractory to first-line drugs (i.e., CDDP, 5-FU) or who experience recurrence following surgery.</p>
      <p>As monotherapy, paclitaxel has been shown to result in a response rate of 26% in gastric cancer patients with previously treated by surgery and 21% in those with prior chemotherapy. Remarkably, paclitaxel is the only monotherapy shown to increase MST to longer than 300 days in patients with advanced and recurrent gastric cancer, regardless of prior treatment history [<xref ref-type="bibr" rid="B24">24</xref>]. Recently, some cases responding to paclitaxel treatment were reported. Chiba <italic>et al., </italic>reported the case of AFP-producing hepatoid adenocarcinoma in association with Barrett's esophagus with multiple liver metastases responding to paclitaxel/CDDP [<xref ref-type="bibr" rid="B25">25</xref>]. Hirashima <italic>et al., </italic>reported the successful bi-weekly paclitaxel treatment of an AFP-producing gastric cancer [<xref ref-type="bibr" rid="B11">11</xref>], however, there was no English literature which described the efficacy of paclitaxel for AFP-producing gastric cancers.</p>
      <p>In our patient, we first used TS-1 and paclitaxel combination chemotherapy. Initially, the patient's AFP levels dramatically decreased and CT showed regression of metastatic liver tumors; however, multiple new liver metastases appeared and serum AFP levels increased after 5 months. Furthermore, the patient suffered an ileus due to peritonitis carcinomatous. Consequentially, we used combination 5-FU and paclitaxel chemotherapy with subsequent paclitaxel monotherapy as second-line treatment. This regimen resulted in the disappearance or reduction in size of many liver metastases, and greatly improved the patient's quality of life. The most significant toxicity, leukopenia, was effectively controlled with granulocyte colony-stimulating factors.</p>
    </sec>
    <sec>
      <title>Conclusion</title>
      <p>To our knowledge, this is the first case report in the English literature of an AFP-producing gastric cancer associated with multiple liver metastases that was successfully treated with paclitaxel. We consider this rare case to be of significant value with respect to the treatment of AFP-producing gastric cancer with multiple liver metastases. We feel that combining surgery with chemotherapy such as paclitaxel will lead to a better prognosis in such cases. We also believe that our protocol is an effective and safe treatment for liver metastases associated with AFP-producing gastric cancer. Nevertheless, further clinical evaluation of this regimen in advanced AFP-producing gastric cancer with liver metastases is required.</p>
    </sec>
    <sec>
      <title>Competing interests</title>
      <p>The author(s) declare that they have no competing interests.</p>
    </sec>
    <sec>
      <title>Authors' contributions</title>
      <p>HT, HS, HT, NO, and TM conducted the clinical examination and surgery. TW, MS, YO, HF, AY, and YA performed pathological analysis. HT, HS, NO, and AY participated in the design of the study. TM conceived of the study, and participated in its design and coordination.</p>
      <p>All authors read and approved the final manuscript.</p>
    </sec>
  </body>
  <back>
    <ack>
      <sec>
        <title>Acknowledgements</title>
        <p>Written consent was obtained from the patient for publication of study.</p>
      </sec>
    </ack>
    <ref-list>
      <ref id="B1">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bergstrand</surname>
              <given-names>CG</given-names>
            </name>
            <name>
              <surname>Czar</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Demonstration of a new protein fraction in serum from the human fetus</article-title>
          <source>Scand J Clin Lab Invest</source>
          <year>1956</year>
          <volume>8</volume>
          <fpage>174</fpage>
          <pub-id pub-id-type="pmid">13351554</pub-id>
        </citation>
      </ref>
      <ref id="B2">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bourreille</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Metayer</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Sauger</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Matray</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Fondimare</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Existence of alpha-fetoprotein during gastric-origin secondary cancer of the liver</article-title>
          <source>Presse Med</source>
          <year>1970</year>
          <volume>78</volume>
          <fpage>1277</fpage>
          <lpage>1278</lpage>
          <pub-id pub-id-type="pmid">5426134</pub-id>
        </citation>
      </ref>
      <ref id="B3">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Alpert</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Pinn</surname>
              <given-names>VW</given-names>
            </name>
            <name>
              <surname>Isselbacher</surname>
              <given-names>KJ</given-names>
            </name>
          </person-group>
          <article-title>Alpha-fetoprotein in a patient with gastric carcinoma metastatic to the liver</article-title>
          <source>N Engl J Med</source>
          <year>1971</year>
          <volume>285</volume>
          <fpage>1058</fpage>
          <lpage>1059</lpage>
          <pub-id pub-id-type="pmid">4106197</pub-id>
        </citation>
      </ref>
      <ref id="B4">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Koide</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Nishio</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Igarashi</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Kajikawa</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Adachi</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Amano</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Alpha-fetoprotein-producing gastric cancer: histochemical analysis of cell proliferation, apoptosis, and angiogenesis</article-title>
          <source>Am J Gastroenterol</source>
          <year>1999</year>
          <volume>94</volume>
          <fpage>1658</fpage>
          <lpage>1663</lpage>
          <pub-id pub-id-type="pmid">10364040</pub-id>
        </citation>
      </ref>
      <ref id="B5">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wakasugi</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Akamo</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Takeyama</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Hasegawa</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Teranishi</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Manabe</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Solitary intraperitoneal recurrence of alpha-fetoprotein-producing gastric carcinoma: report of a case</article-title>
          <source>Surg Today</source>
          <year>2002</year>
          <volume>32</volume>
          <fpage>429</fpage>
          <lpage>443</lpage>
          <pub-id pub-id-type="pmid">12061695</pub-id>
          <pub-id pub-id-type="doi">10.1007/s005950200069</pub-id>
        </citation>
      </ref>
      <ref id="B6">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Takahashi</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Ohta</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Mai</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Angiogenesis of AFP producing gastric carcinoma: correlation with frequent liver metastasis and its inhibition by anti-AFP antibody</article-title>
          <source>Oncol Rep</source>
          <year>2004</year>
          <volume>11</volume>
          <fpage>809</fpage>
          <lpage>813</lpage>
          <pub-id pub-id-type="pmid">15010877</pub-id>
        </citation>
      </ref>
      <ref id="B7">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gonda</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Ishida</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Higuchi</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Hirukawa</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Nakajima</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Hojo</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Mishima</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>A case of AFP (alpha-fetoprotein) producing gastric cancer successfully treated with EAP (etoposide, adriamycin, cisplatin) therapy</article-title>
          <source>Jpn J Cancer Chemother</source>
          <year>1994</year>
          <volume>21</volume>
          <fpage>1659</fpage>
          <lpage>1663</lpage>
        </citation>
      </ref>
      <ref id="B8">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hoshino</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Kawaguchi</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Unate</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Nitta</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Fukui</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Ikeda</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Tsujitani</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>A case of AFP (alpha-fetoprotein) producing gastric cancer successfully treated with FEP (5-FU, Epirubicin, cisplatin) therapy by continuous venous daily infusion of 5-FU and low-dose CDDP</article-title>
          <source>Jpn J Cancer Chemother</source>
          <year>1996</year>
          <volume>23</volume>
          <fpage>1197</fpage>
          <lpage>1200</lpage>
        </citation>
      </ref>
      <ref id="B9">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yabusaki</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Nashimoto</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Tanaka</surname>
              <given-names>O</given-names>
            </name>
          </person-group>
          <article-title>A case of AFP-producing gastric cancer after curative operation effectively treated with chemotherapies including hepatic arterial infusion therapy</article-title>
          <source>Jpn J Cancer Chemother</source>
          <year>2000</year>
          <volume>27</volume>
          <fpage>735</fpage>
          <lpage>738</lpage>
        </citation>
      </ref>
      <ref id="B10">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shimada</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Hayashi</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Marutsuka</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Baba</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Yokoyama</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Iyama</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Ogawa</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Irinotecan plus low-dose cisplatin for alpha-fetoprotein-producing gastric carcinoma with multiple liver metastases: report of two cases</article-title>
          <source>Surg Today</source>
          <year>2002</year>
          <volume>32</volume>
          <fpage>1075</fpage>
          <lpage>1080</lpage>
          <pub-id pub-id-type="pmid">12541026</pub-id>
          <pub-id pub-id-type="doi">10.1007/s005950200217</pub-id>
        </citation>
      </ref>
      <ref id="B11">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hirashima</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Kitajima</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Sugi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kagawa</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Kumamoto</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Murakami</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Fujioka</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Noguchi</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Successful bi-weekly paclitaxel treatment of an AFP-producing gastric cancer patient with peritoneal dissemination and multiple liver metastasis (in Japanese)</article-title>
          <source>Jpn J Cancer Chemothe</source>
          <year>2006</year>
          <volume>33</volume>
          <fpage>517</fpage>
          <lpage>519</lpage>
        </citation>
      </ref>
      <ref id="B12">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <collab>Japanese Gastric Cancer Association</collab>
          </person-group>
          <article-title>Japanese classification of gastric carcinoma, 2nd English edition</article-title>
          <source>Gastric Cancer</source>
          <year>1998</year>
          <volume>1</volume>
          <fpage>10</fpage>
          <lpage>24</lpage>
          <pub-id pub-id-type="pmid">11957040</pub-id>
          <pub-id pub-id-type="doi">10.1007/PL00011681</pub-id>
        </citation>
      </ref>
      <ref id="B13">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Motoyama</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Aizawa</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Watanabe</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Fukase</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Saito</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>alpha-Fetoprotein producing gastric carcinomas: a comparative study of three different subtypes</article-title>
          <source>Acta Pathol Jpn</source>
          <year>1993</year>
          <volume>43</volume>
          <fpage>654</fpage>
          <lpage>651</lpage>
          <pub-id pub-id-type="pmid">7508672</pub-id>
        </citation>
      </ref>
      <ref id="B14">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Antonini</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Forgiarini</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Chiara</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Briani</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Sacchi</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Hepatoid adenocarcinoma of the stomach. Case report and review of the literature</article-title>
          <source>Pathologica</source>
          <year>1997</year>
          <volume>89</volume>
          <fpage>310</fpage>
          <lpage>316</lpage>
          <pub-id pub-id-type="pmid">9380425</pub-id>
        </citation>
      </ref>
      <ref id="B15">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Inagawa</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Shimazaki</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Hori</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Yoshimi</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Adachi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kawamoto</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Fukao</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Itabashi</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Hepatoid adenocarcinoma of the stomach</article-title>
          <source>Gastric Cancer</source>
          <year>2001</year>
          <volume>4</volume>
          <fpage>43</fpage>
          <lpage>52</lpage>
          <pub-id pub-id-type="pmid">11706627</pub-id>
          <pub-id pub-id-type="doi">10.1007/s101200100016</pub-id>
        </citation>
      </ref>
      <ref id="B16">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Amemiya</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Kono</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Mori</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Takahashi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ichihara</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Iizuka</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Sekikawa</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Matsumoto</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>High frequency of c-Met expression in gastric cancers producing alpha-fetoprotein</article-title>
          <source>Oncology</source>
          <year>2000</year>
          <volume>59</volume>
          <fpage>145</fpage>
          <lpage>51</lpage>
          <pub-id pub-id-type="pmid">10971174</pub-id>
          <pub-id pub-id-type="doi">10.1159/000012152</pub-id>
        </citation>
      </ref>
      <ref id="B17">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kamei</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kono</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Amemiya</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Takahashi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Sugai</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Ichihara</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Fujii</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Matsumoto</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Evaluation of VEGF and VEGF-C expression in gastric cancer cells producing alpha-fetoprotein</article-title>
          <source>J Gastroenterol</source>
          <year>2003</year>
          <volume>38</volume>
          <fpage>540</fpage>
          <lpage>547</lpage>
          <pub-id pub-id-type="pmid">12825129</pub-id>
        </citation>
      </ref>
      <ref id="B18">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kono</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Amemiya</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Sekikawa</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Iizuka</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Takahashi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Fujii</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Matsumoto</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Clinicopathologic features of gastric cancers producing alpha-fetoprotein</article-title>
          <source>Dig Surg</source>
          <year>2002</year>
          <volume>19</volume>
          <fpage>359</fpage>
          <lpage>365</lpage>
          <pub-id pub-id-type="pmid">12435906</pub-id>
          <pub-id pub-id-type="doi">10.1159/000065838</pub-id>
        </citation>
      </ref>
      <ref id="B19">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ihling</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Schaefer</surname>
              <given-names>HE</given-names>
            </name>
            <name>
              <surname>Baumgartner</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Riede</surname>
              <given-names>UN</given-names>
            </name>
          </person-group>
          <article-title>Hepatoid adenocarcinoma of the stomach: a case report</article-title>
          <source>Gen Diagn Pathol</source>
          <year>1995</year>
          <volume>141</volume>
          <fpage>61</fpage>
          <lpage>65</lpage>
          <pub-id pub-id-type="pmid">8542509</pub-id>
        </citation>
      </ref>
      <ref id="B20">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nakajima</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Ota</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Ishihara</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Oyama</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Nishi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ohashi</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Yanagisawa</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Combined intensive chemotherapy and radical surgery for incurable gastric cancer</article-title>
          <source>Ann Surg Oncol</source>
          <year>1997</year>
          <volume>4</volume>
          <fpage>203</fpage>
          <lpage>208</lpage>
          <pub-id pub-id-type="pmid">9142380</pub-id>
          <pub-id pub-id-type="doi">10.1007/BF02306611</pub-id>
        </citation>
      </ref>
      <ref id="B21">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kochi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Fujii</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kaiga</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Takahashi</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Morishita</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Kobayashi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kasakura</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Takayama</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>FLEP chemotherapy for alpha-fetoprotein-producing gastric cancer</article-title>
          <source>Oncology</source>
          <year>2004</year>
          <volume>66</volume>
          <fpage>445</fpage>
          <lpage>449</lpage>
          <pub-id pub-id-type="pmid">15452373</pub-id>
          <pub-id pub-id-type="doi">10.1159/000079498</pub-id>
        </citation>
      </ref>
      <ref id="B22">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sakata</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Ohtsu</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Horikoshi</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Sugimachi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Mitachi</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Taguchi</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1M tegafur-0.4M gimestat-1M otastat potassium) in advanced gastric cancer patients</article-title>
          <source>Eur J Cancer</source>
          <year>1998</year>
          <volume>34</volume>
          <fpage>1715</fpage>
          <lpage>1720</lpage>
          <pub-id pub-id-type="pmid">9893658</pub-id>
          <pub-id pub-id-type="doi">10.1016/S0959-8049(98)00211-1</pub-id>
        </citation>
      </ref>
      <ref id="B23">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Horwitz</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Taxol (paclitaxel): mechanisms of action</article-title>
          <source>Ann Oncol</source>
          <year>1994</year>
          <volume>5</volume>
          <fpage>S3</fpage>
          <lpage>S6</lpage>
          <pub-id pub-id-type="pmid">7865431</pub-id>
        </citation>
      </ref>
      <ref id="B24">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yamada</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Shirao</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Ohtsu</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Boku</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Hyodo</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Saitoh</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Miyata</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Taguchi</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions</article-title>
          <source>Ann Oncol</source>
          <year>2001</year>
          <volume>12</volume>
          <fpage>1133</fpage>
          <lpage>1137</lpage>
          <pub-id pub-id-type="pmid">11583196</pub-id>
          <pub-id pub-id-type="doi">10.1023/A:1011680507956</pub-id>
        </citation>
      </ref>
      <ref id="B25">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chiba</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Yoshioka</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Sakayori</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Mikami</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Miyazaki</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Akiyama</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Otsuka</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Yamaura</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Shibata</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Kato</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kato</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ishioka</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>AFP-producing hepatoid adenocarcinoma in association with Barrett's esophagus with multiple liver metastasis responding to paclitaxel/CDDP: a case report</article-title>
          <source>Anticancer Res</source>
          <year>2005</year>
          <volume>25</volume>
          <fpage>2965</fpage>
          <lpage>2968</lpage>
          <pub-id pub-id-type="pmid">16080552</pub-id>
        </citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
